Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 15:34 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma
NCT03301636 · NewLink Genetics Corporation · PHASE2 · terminated · last registry update 2022-09-27 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “Sponsor termination, not related to efficacy, safety or feasibility.” | – | Registry record, NewLink Genetics Corporation |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against PDCD1 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2023-08-21Phase 3 first posted: Fudan University, Camrelizumab Plus Chemotherapy and Famitinib + Camrelizumab Plus Chemotherapy (NCT05999149)
- 2023-06-27Phase 3 first posted: Amgen, Sotorasib + Pembrolizumab (NCT05920356)
- 2023-06-06Results posted on the registry: Massachusetts General Hospital, Pembrolizumab (NCT03279692)
- 2023-03-23Results posted on the registry: City of Hope Medical Center, Cyclophosphamide + Cytokine-based Biologic Agent IRX-2 (NCT03918499)
- 2022-12-01Phase 3 first posted: Gilead Sciences, Sacituzumab govitecan-hziy (SG) + Pembrolizumab (NCT05633654)
- 2022-11-08Phase 3 first posted: Regeneron Pharmaceuticals, Fianlimab + Cemiplimab (NCT05608291)
- 2022-09-27Phase 3 first posted: Daiichi Sankyo, Datopotamab Deruxtecan + Pembrolizumab (NCT05555732)
- 2022-08-30Phase 3 first posted: Hutchmed, fruquintinib+sintilimab + axitinib / everolimus (NCT05522231)
- 2022-06-30Results posted on the registry: City of Hope Medical Center, Pembrolizumab (NCT02830594)
- 2022-06-23Phase 3 first posted: Second Affiliated Hospital, Zhejiang University, School of Medicine, Sintilimab + Carboplatin (NCT05429463)
- 2022-01-21Phase 3 first posted: ARCAGY/ GINECO GROUP, Carboplatin-Paclitaxel + Dostarlimab (NCT05201547)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision